Researcher Profile

Researcher Profile

Patricia McLaughlin, MS, DEd

Patricia McLaughlin, MS, DEd

Professor, Department of Neural and Behavioral Sciences
Scientific Program:Next-Generation Therapies
pxm9@psu.edu

Research Interests

Dr. Patricia McLaughlin’s research focuses on the Opioid Growth Factor (OGF) – OGF receptor (OGFr) pathway and mechanisms of action in homeostasis and disease. Early collaborative work with Dr. Ian Zagon resulted in the identification of [Met5]-enkephalin as the endogenous ligand for the OGF-OGFr pathway. Subsequently, a new nuclear-associated receptor was identified and termed OGFr. One group in the laboratory has characterized and cloned the OGFr gene in human, mouse and rat. Protein chemistry studies, along with structural biology, determined that the OGFr is a uniquely unstructured nuclear receptor. The mechanism of action was determined to involve inhibition of DNA synthesis with the specific mechanistic pathway involving upregulation of cyclin-dependent inhibitory kinases p16 and p21. OGF action is receptor-mediated, reversible, and not associated with apoptosis/necrosis. OGF is tissue non-specific and has been identified in proliferating cells and tissues derived from all 3 dermal layers.

Currently, the lab’s work is translational, focusing on disease-based pathways that are characterized by a perturbation in the OGF-OGFr axis. Consequences of receptor blockade of the OGF-OGFr axis are being studied with an emphasis on the etiology and treatment of complications (e.g., delayed wound healing, dry eye, impaired bone composition) arising from long-term diabetes (Type 1 or Type 2). These investigations (humans and animal models) focus on treatment options and utilize confocal microscopy, animal surgery, immunohistochemistry and tissue culture.

In another series of studies, the lab is testing the hypothesis that down-regulation of the inhibitory OGF peptide plays a role in multiple sclerosis and other autoimmune diseases. The lab is also currently validating serum biomarkers and cytokine expression profiles that correspond to changes in behavior and MRI imaging that may be related to disease progression and response to therapy. The clinical and animal research is both qualitative and quantitative in design and is supported by NIH, ADA, TSF (PA) and foundations.

  • Opioid Analgesics
  • Intercellular Signaling Peptides and Proteins
  • Naltrexone
  • methionine-enkephalin receptor
  • Growth
  • Enkephalins
  • Neoplasms
  • Opioid Receptors
  • Cell Proliferation
  • Narcotic Antagonists
  • DNA
  • Brain

Recent Publications

2021

Purushothaman, I, Zagon, IS, Sassani, J & McLaughlin, PJ 2021, 'Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats', Experimental and Therapeutic Medicine, vol. 22, no. 1, 687. https://doi.org/10.3892/etm.2021.10119
Purushothaman, I, Zagon, IS, Sassani, J, Zhou, S & McLaughlin, PJ 2021, 'Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF', Physiology and Behavior, vol. 237, 113436. https://doi.org/10.1016/j.physbeh.2021.113436
Patel, C, Thomas, G, Zomorodi, N, Zagon, IS & McLaughlin, PJ 2021, 'β-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis', Multiple Sclerosis and Related Disorders, vol. 50, 102868. https://doi.org/10.1016/j.msard.2021.102868

2020

Zagon, IS, Sassani, JW, Purushothaman, I & McLaughlin, PJ 2021, 'Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications', Experimental Biology and Medicine, vol. 246, no. 5, pp. 629-636. https://doi.org/10.1177/1535370220972060
Zagon, IS, Sassani, JW, Purushothaman, I & McLaughlin, PJ 2020, 'Dysregulation of the OGF–OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat', Experimental Biology and Medicine, vol. 245, no. 15, pp. 1414-1421. https://doi.org/10.1177/1535370220940273
Patel, C, Meadowcroft, MD, Zagon, IS & McLaughlin, PJ 2020, '[Met5]-enkephalin preserves diffusion metrics in EAE mice', Brain Research Bulletin, vol. 165, pp. 246-252. https://doi.org/10.1016/j.brainresbull.2020.10.015

2019

Titunick, MB, Lewis, GS, Cain, JD, Zagon, IS & McLaughlin, PJ 2019, 'Blockade of the OGF-OGFr pathway in diabetic bone', Connective Tissue Research, vol. 60, no. 6, pp. 521-529. https://doi.org/10.1080/03008207.2019.1593396
McLaughlin, PJ, Sassani, JW, Titunick, MB & Zagon, IS 2019, 'Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes', BMC Ophthalmology, vol. 19, no. 1, 35. https://doi.org/10.1186/s12886-019-1044-y

2018

Zagon, IS & McLaughlin, PJ 2018, 'Intermittent blockade of OGFr and treatment of autoimmune disorders', Experimental Biology and Medicine, vol. 243, no. 17-18, pp. 1323-1330. https://doi.org/10.1177/1535370218817746

2017

Ludwig, MD, Zagon, IS & McLaughlin, PJ 2017, 'Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis', Brain Research Bulletin, vol. 134, pp. 1-9. https://doi.org/10.1016/j.brainresbull.2017.06.015
Stockdale, DP, Titunick, MB, Biegler, JM, Reed, JL, Hartung, AM, Wiemer, DF, McLaughlin, PJ & Neighbors, JD 2017, 'Selective opioid growth factor receptor antagonists based on a stilbene isostere', Bioorganic and Medicinal Chemistry, vol. 25, no. 16, pp. 4464-4474. https://doi.org/10.1016/j.bmc.2017.06.035
McLaughlin, PJ, Cain, JD, Titunick, MB, Sassani, JW & Zagon, IS 2017, 'Topical Naltrexone is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds', Advances in Wound Care, vol. 6, no. 9, pp. 279-288. https://doi.org/10.1089/wound.2016.0725

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)